Abstract
Mutations of the PIT1/POU1F1 gene are responsible for a rare variant of anterior hypopituitarism, including deficiency of growth hormone, prolactin and thyrotropin. In 8 ethnically diverse POU1F1-deficient patients (4 different mutations) with normal circulating levels of cortisol and adrenocorticotropic hormone, and with spontaneous onset and progression of puberty, we observed an absence or delay of adrenarche (median circulating dehydroepiandrosterone-sulfate –6.2 SD); in each of the 4 postmenarcheal females, pubarche (i.e. appearance of pubic hair) was also absent or delayed. The absence/delay of adrenarche in POU1F1-deficient patients and the absence/delay of pubarche in POU1F1-deficient females suggest that a POU1F1-dependent factor contributes to the normal development of adrenarche and female pubarche.
References
1.
Cohen LE, Wondisford FE, Radovick S: Role of Pit-1 in the gene expression of growth hormone, prolactin and thyrotropin. Endocrinol Metab Clin North Am 1996;25:523–540.
2.
Ohta K, Nobukuni Y, Mitsubuchi H, Ohta T, Tohma T, Jinno Y, Endo F, Matsuda I: Characterization of the gene encoding human pituitary-specific transcription factor, Pit-1. Gene 1992;122:387–388.
3.
de Zegher F, Pernasetti F, Vanhole C, Devlieger H, Van Den Berghe G, Martial J: The prenatal role of thyroid hormone evidenced by fetomaternal Pit-1 deficiency. J Clin Endocrinol Metab 1995;80:3127–3130.
4.
Ohta K, Nobukuni Y, Mitsubuchi H, Fujimoto S, Matsuo N, Inagaki H, Endo F, Matsuda I: Mutations in the PIT-1 gene in children with combined pituitary hormone deficiency. Biochem Biophys Res Commun 1992;189:851–855.
5.
Tatsumi K, Miyai K, Notomi T, Kaibe K, Amino N, Mizuno Y, Kohno H: Cretinism with combined hormone deficiency caused by a mutation in the PIT1 gene. Nature Genet 1992;1:56–58.
6.
Irie Y, Tatsumi K, Ogawa M, Kamijo T, Preeyasombat C, Suprasongsin C, Amino N: A novel E250X mutation of the PIT1 gene in a patient with combined pituitary hormone deficiency. Endocr J1995;42:351–354.
7.
Pfaffle RW, DiMattia GE, Parks JS, Brown MR, Wit JM, Jansen M, Van der Nat H, Van der Brande JL, Rosenfeld MG, Ingraham HA: Mutation of the POU-specific domain of Pit-1 and hypopituitarism without pituitary hypoplasia. Science 1992;257:1118–1121.
8.
Salemi S, Besson A, Eble A, Gallati S, Pfaffle RW, Mullis PE: New N-terminal located mutation (Q4ter) within the POU1F1-gene (PIT-1) causes recessive combined pituitary hormone deficiency and variable phenotype. Growth Horm IGF Res2003;13:264–268.
9.
Albright F, Smith P, Fraser R: A syndrome characterized by primary ovarian insufficiency and decreased stature: report of 11 cases with a digression on hormonal control of axillary and pubic hair. Am J Med Sci 1942;204:625–648.
10.
Parker LN: Adrenarche. Endocrinol Metab Clin North Am 1991;20:71–83.
11.
Ishihara F, Komatsu M, Yamada T, Aizawa T, Ichikawa K, Takasu N, Komiya I: Role of dehydroepiandrosterone and dehydroepiandrosterone sulphate for the maintenance of axillary hair in women. Horm Metab Res 1993;25:34–36.
12.
Parker LN: Control of adrenal androgen secretion. Endocrinol Metab Clin North Am 1991;20:401–421.
13.
Gell JS, Carr BR, Sasano H, Atkins B, Margraf L, Mason JI, Rainey WE: Adrenarche results from development of a 3β-hydroxysteroid dehydrogenase-deficient adrenal reticularis. J Clin Endocrinol Metab 1998;83:3695–3701.
14.
Weber A, Clark AJ, Perry LA, Honour JW, Savage MO: Diminished adrenal androgen secretion in familial glucocorticoid deficiency implicates a significant role for ACTH in the induction of adrenarche. Clin Endocrinol (Oxf) 1997;46:431–437.
15.
Ibáñez L, Potau N, Marcos MV, de Zegher F: Recognition of corticotropin-releasing hormone as adrenal androgen secretagogue. Pediatr Res 1999;46:351–353.
16.
Parker LN, Odell WD: Evidence for existence of cortical androgen-stimulating hormone. Am J Physiol 1979;236:E616–E620.
17.
Warne GL, Carter JN, Faiman C, Reyes FI, Winter JS: Hormonal changes in girls with precocious adrenarche: a possible role for estradiol or prolactin. J Pediatr 1978;92:743–747.
18.
Marshall WA, Tanner JM: Variations in the pattern of pubertal changes in girls. Arch Dis Child 1969;44:291–303.
19.
Marshall WA, Tanner JM: Variations in the pattern of pubertal changes in boys.Arch Dis Child 1970;45:13–23.
20.
Pernasetti F, Milner R, Al Ashwal A, de Zegher F, Chavez V, Muller M, Martial J: Pro239Ser: A novel recessive mutation of the Pit-1 gene in seven Middle Eastern children with growth hormone, prolactin, and thyrotropin deficiency. J Clin Endocrinol Metabol1998;83:2079–2083.
21.
Potau N, Ibanez L, Sentis M, Carrascosa A: Sexual dimorphism in the maturation of the pituitary-gonadal axis, assessed by GnRH agonist challenge. Eur J Endocrinol 1999;141:27–34.
22.
Arnhold IJ, Nery M, Brown MR, Voss TC, Vanderheyden TC, Adess ME, Hurley DL, Wajchenberg BL, Parks JS: Clinical and molecular characterization of a Brazilian patient with Pit-1 deficiency. J Pediatr Endocrinol Metab 1998;11:623–630.
23.
Auchus RJ, Rainey WE: Adrenarche: physiology, biochemistry and human disease. Clin Endocrinol 2004;60:288–296.
24.
Lee PA, Kowarski A, Migeon CJ, Blizzard RM: Lack of correlation between gonadotropin and adrenal androgen levels in agonadal children. J Clin Endocrinol Metab 1975;40:664–669.
25.
Sklar CA, Kaplan SL, Grumbach MM: Evidence for dissociation between adrenarche and gonadarche: studies in patients with idiopathic precocious puberty, gonadal dysgenesis, isolated gonadotropin deficiency, and constitutionally delayed growth and adolescence. J Clin Endocrinol Metab 1980;51:548–556.
26.
Martin DD, Schweizer R, Schwarze CP, Elmlinger MW, Ranke MB, Binder G: The early dehydroepiandrosterone sulfate rise of adrenarche and the delay of pubarche indicate primary ovarian failure in Turner syndrome. J Clin Endocrinol Metab 2004;89:1164–1168.
27.
Mellon SH, Shively JE, Miller WJ: Human proopiomelanocortin-(76–96), a proposed androgen stimulatory hormone, does not affect steroidogenesis in cultured human fetal adrenal cells. J Clin Endocrinol Metab 1991;72:19–22.
28.
Ilondo MM, Vanderschueren-Lodeweyckx M, Vlietinck R, Pizarro M, Malvaux P, Eggermont E, Eeckels R: Plasma androgens in children and adolescents. II. A longitudinal study in patients with hypopituitarism. Horm Res 1982;16:78–95.
29.
Apter D, Pakarinen A, Hammond GL, Vihko R: Adrenocortical function in puberty. Acta Paediatr Scand 1979;68:599–604.
30.
Hauffa BP, Kaplan SL, Grumbach MM: Dissociation between plasma adrenal androgens and cortisol in Cushing’s disease and ectopic ACTH-producing tumour: relation to adrenarche. Lancet 1984;1:1373–1375.
31.
Kreitzer P, Blethen S, Festa R, Chasalow F: Dehydroepiandrosterone sulfate levels are not suppressible by glucocorticoids before adrenarche. J Clin Endocrinol Metab 1989;69:1309–1311.
32.
Voutetakis A, Livadas S, Sertedaki A, Maniati-Christidi M, Dacou-Voutetakis C: Insufficient adrenarche in patients with combined pituitary hormone deficiency caused by a PROP-1 gene defect. J Pediatr Endocrinol Metab 2001;14:1107–1111.
33.
Remer T, Manz F: Role of nutritional status in the regulation of adrenarche. J Clin Endocrinol Metab 1999;84:3936–3944.
34.
Cizza G, Dorn LD, Lotsikas A, Sereika S, Rotenstein D, Chrousos GP: Circulating plasma leptin and IGF-1 levels in girls with premature adrenarche: potential implications of a preliminary study. Horm Metab Res 2001;33:138–143.
35.
Biason-Lauber A, Zachmann M, Schoenle EJ: Effect of leptin on CYP17 enzymatic activities in human adrenal cells: new insight in the onset of adrenarche. Endocrinology 2000;141:1446–1454.
36.
Dutton CM, Joba W, Spitzweg C, Heufelder AE, Bahn RS: Thyrotropin receptor expression in adrenal, kidney, and thymus. Thyroid 1997;7:879–884.
37.
Glasow A, Breidert M, Haidan A, Anderegg U, Kelly PA, Bornstein SR: Functional aspects of the effect of prolactin (PRL) on adrenal steroidogenesis and distribution of the PRL receptor in the human adrenal gland. J Clin Endocrinol Metab1996;81:3103–3111.
38.
Calogero AE, Weber RFA, Raiti F, Burrello N, Moncada ML, Mongioi A, D’Agata R: Involvement of corticotropin-releasing hormone and endogenous opioid peptides in prolactin-suppressed gonadotropin-releasing hormone release in vitro. Neuroendocrinology 1994;60:291–296.
39.
Higuchi K, Nawata H, Maki T, Higashizima M, Kato K, Ibayashi H: Prolactin has a direct effect on adrenal androgen secretion. J Clin Endocrinol Metab 1984;59:714–718.
40.
Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA: Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998;19:225–268.
41.
Ibáñez L, Potau N, Marcos MV, de Zegher F: Corticotropin-releasing hormone: a potent androgen secretagogue in girls with hyperandrogenism after precocious pubarche. J Clin Endocrinol Metab 1999;84:4602–4606.
42.
Van den Berghe G, de Zegher F, Wouters P, Schetz M, Verwaest C, Ferdinande P, Lauwers P: Dehydroepiandrosterone sulphate in critical illness: effect of dopamine. Clin Endocrinol 1995;43:457–463.
43.
Schiebinger RJ, Chrousos GP, Cutler GB Jr, Loriaux DL: The effect of serum prolactin on plasma adrenal androgens and the production and metabolic clearance rate of dehydroepiandrosterone sulfate in normal and hyperprolactinemic subjects. J Clin Endocrinol Metab 1986;62:202–209.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
